loading...| Preferred Name |
Edatrexate |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C958 |
| ALT_DEFINITION |
An anticancer drug that belongs to a family of drugs called antimetabolites. |
| CAS_Registry |
80576-83-6 |
| Chemical_Formula |
C22H25N7O5 |
| code |
C958 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. (NCI04) |
| FDA_UNII_Code |
JT4X6Z1HRR |
| FULL_SYN |
CGP-30694 EDAM N-[4-[1-[(2,4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic Acid Edatrexate 10-EDAM N-[4-[1-[(2, 4-Diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic acid edatrexate 10-EdAM 10-Ethyl-10-deaza-aminopterin EDATREXATE |
| Is_Value_For_GDC_Property | |
| label |
Edatrexate |
| Legacy Concept Name |
Edatrexate |
| Maps_To |
Edatrexate |
| NCI_Drug_Dictionary_ID |
40887 |
| NSC Number |
626715 |
| PDQ_Closed_Trial_Search_ID |
40887 |
| PDQ_Open_Trial_Search_ID |
40887 |
| Preferred_Name |
Edatrexate |
| prefixIRI |
Thesaurus:C958 |
| prefLabel |
Edatrexate |
| Semantic_Type |
Pharmacologic Substance Amino Acid, Peptide, or Protein |
| UMLS_CUI |
C0044667 |
| subClassOf |